JP2022520080A5 - - Google Patents
Info
- Publication number
- JP2022520080A5 JP2022520080A5 JP2021546888A JP2021546888A JP2022520080A5 JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5 JP 2021546888 A JP2021546888 A JP 2021546888A JP 2021546888 A JP2021546888 A JP 2021546888A JP 2022520080 A5 JP2022520080 A5 JP 2022520080A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- gene
- adenosine
- base editor
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024193416A JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805271P | 2019-02-13 | 2019-02-13 | |
| US62/805,271 | 2019-02-13 | ||
| US201962850919P | 2019-05-21 | 2019-05-21 | |
| US62/850,919 | 2019-05-21 | ||
| US201962852224P | 2019-05-23 | 2019-05-23 | |
| US201962852228P | 2019-05-23 | 2019-05-23 | |
| US62/852,228 | 2019-05-23 | ||
| US62/852,224 | 2019-05-23 | ||
| US201962873138P | 2019-07-11 | 2019-07-11 | |
| US62/873,138 | 2019-07-11 | ||
| US201962888867P | 2019-08-19 | 2019-08-19 | |
| US62/888,867 | 2019-08-19 | ||
| US201962931722P | 2019-11-06 | 2019-11-06 | |
| US62/931,722 | 2019-11-06 | ||
| US201962941569P | 2019-11-27 | 2019-11-27 | |
| US62/941,569 | 2019-11-27 | ||
| US202062966526P | 2020-01-27 | 2020-01-27 | |
| US62/966,526 | 2020-01-27 | ||
| PCT/US2020/018073 WO2020168051A1 (en) | 2019-02-13 | 2020-02-13 | Methods of editing a disease-associated gene using adenosine deaminase base editors, including for the treatment of genetic disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193416A Division JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022520080A JP2022520080A (ja) | 2022-03-28 |
| JP2022520080A5 true JP2022520080A5 (cg-RX-API-DMAC7.html) | 2023-02-21 |
| JP7586601B2 JP7586601B2 (ja) | 2024-11-19 |
Family
ID=72045106
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546888A Active JP7586601B2 (ja) | 2019-02-13 | 2020-02-13 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
| JP2024193416A Pending JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024193416A Pending JP2025032080A (ja) | 2019-02-13 | 2024-11-05 | 遺伝的疾患の治療用を含めアデノシンデアミナーゼ塩基エディターを用いて疾患関連遺伝子を編集する方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230140953A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3924484A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7586601B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210127206A (cg-RX-API-DMAC7.html) |
| CN (2) | CN114040970B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020223306B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3128876A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020168051A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3765615T3 (pl) | 2018-03-14 | 2023-11-13 | Arbor Biotechnologies, Inc. | Nowe enzymy i układy crispr ukierunkowane na dna |
| WO2019217942A1 (en) | 2018-05-11 | 2019-11-14 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| WO2019222555A1 (en) | 2018-05-16 | 2019-11-21 | Arbor Biotechnologies, Inc. | Novel crispr-associated systems and components |
| KR20210055733A (ko) | 2018-09-07 | 2021-05-17 | 빔 테라퓨틱스, 인크. | 핵염기 편집 시스템을 전달하기 위한 조성물 및 방법 |
| EP3850088A4 (en) | 2018-09-07 | 2023-07-19 | Beam Therapeutics, Inc. | Compositions and methods for improving base editing |
| JP7646552B2 (ja) | 2019-01-31 | 2025-03-17 | ビーム セラピューティクス インク. | 低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ |
| US12600971B2 (en) | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| CN114096666B (zh) | 2019-02-13 | 2025-03-18 | 比姆医疗股份有限公司 | 治疗血红素病变的组合物和方法 |
| WO2020168135A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| CN114040970B (zh) * | 2019-02-13 | 2024-09-27 | 比姆医疗股份有限公司 | 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗 |
| CA3136735A1 (en) | 2019-04-15 | 2020-10-22 | Edigene Inc. | Methods and compositions for editing rnas |
| AU2020313143B2 (en) | 2019-07-12 | 2024-04-04 | Peking University | Targeted RNA editing by leveraging endogenous adar using engineered RNAs |
| US12594301B2 (en) | 2019-09-27 | 2026-04-07 | Beam Therapeutics Inc. | Compositions and methods for treatment of liquid cancers |
| AU2020418228A1 (en) * | 2019-12-30 | 2022-08-18 | Edigene Therapeutics (Beijing) Inc. | Leaper technology based method for treating MPS IH and composition |
| CN116113692A (zh) * | 2020-02-13 | 2023-05-12 | 比姆医疗股份有限公司 | 用于植入碱基编辑细胞的组合物和方法 |
| WO2022027035A1 (en) * | 2020-07-27 | 2022-02-03 | The Children's Hospital Of Philadelphia | In utero and postnatal gene editing and therapy for treatment of monogenic diseases, including mucopolysaccharidosis type 1h and other disorders |
| AU2021347359A1 (en) | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| US20240110177A1 (en) * | 2020-10-21 | 2024-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | A screening platform for adar-recruiting guide rnas |
| EP4323501A1 (en) * | 2021-04-16 | 2024-02-21 | Beam Therapeutics Inc. | Genetic modification of hepatocytes |
| CN117729931A (zh) * | 2021-05-14 | 2024-03-19 | 比姆医疗股份有限公司 | 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法 |
| CA3220738A1 (en) * | 2021-05-21 | 2022-11-24 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| EP4426821A1 (en) * | 2021-11-02 | 2024-09-11 | University of Massachusetts | Nme2cas9 inlaid domain fusion proteins |
| JP2024543208A (ja) * | 2021-12-01 | 2024-11-19 | シェイプ セラピューティクス インコーポレイテッド | Lrrk2を標的としたrna編集のための遺伝子操作されたガイドrna及びポリヌクレオチド |
| CN117187220A (zh) * | 2022-03-08 | 2023-12-08 | 中国科学院遗传与发育生物学研究所 | 腺嘌呤脱氨酶及其在碱基编辑中的用途 |
| CN114686456B (zh) | 2022-05-10 | 2023-02-17 | 中山大学 | 基于双分子脱氨酶互补的碱基编辑系统及其应用 |
| CA3266991A1 (en) * | 2022-09-08 | 2024-03-14 | The University Court Of The University Of Edinburgh | TREATMENT OF RETT SYNDROME |
| WO2024230760A1 (zh) * | 2023-05-09 | 2024-11-14 | 北京齐禾生科生物科技有限公司 | 一种可作用于dna的腺苷脱氨酶及其应用 |
| WO2024233941A1 (en) * | 2023-05-11 | 2024-11-14 | Massachusetts Eye And Ear Infirmary | Base editing approaches to treat abca4-associated stargardt disease |
| EP4713348A1 (en) * | 2023-05-15 | 2026-03-25 | University of Georgia Research Foundation, Inc. | Doubly constrained peptides as allosteric inhibitors of leucine rich repeat kinase 2 |
| CN117965505A (zh) * | 2023-06-28 | 2024-05-03 | 微光基因(苏州)有限公司 | 工程化的腺苷脱氨酶及碱基编辑器 |
| CN120536418A (zh) * | 2024-02-26 | 2025-08-26 | 尧唐(上海)生物科技有限公司 | 一种脱氨酶变体、包含其的碱基编辑器及其应用 |
| WO2025184515A1 (en) * | 2024-02-29 | 2025-09-04 | Vesigen, Inc. | Arrdc1-mediated microvesicle-based delivery of therapeutic agents to cells and tissues of the eye |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012004778A1 (en) * | 2010-07-09 | 2012-01-12 | Ecole Polytechnique Federale De Lausanne (Epfl) | Method for in-vitro monitoring of neuronal disorders and use thereof |
| AU2015332533B2 (en) * | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| WO2018027078A1 (en) * | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| KR20240007715A (ko) * | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| KR102678809B1 (ko) * | 2017-05-18 | 2024-06-26 | 더 브로드 인스티튜트, 인코퍼레이티드 | 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물 |
| CN111328290A (zh) * | 2017-06-26 | 2020-06-23 | 博德研究所 | 用于靶向核酸编辑的基于crispr/cas-腺嘌呤脱氨酶的组合物、系统和方法 |
| CN109306361B (zh) * | 2018-02-11 | 2022-06-28 | 华东师范大学 | 一种新的a/t到g/c碱基定点转换的基因编辑系统 |
| CN109295186B (zh) * | 2018-09-30 | 2023-10-03 | 中山大学 | 一种基于全基因组测序检测腺嘌呤单碱基编辑系统脱靶效应的方法及其在基因编辑中的应用 |
| CN114040970B (zh) * | 2019-02-13 | 2024-09-27 | 比姆医疗股份有限公司 | 使用腺苷脱氨酶碱基编辑器编辑疾病相关基因的方法,包括遗传性疾病的治疗 |
-
2020
- 2020-02-13 CN CN202080028186.5A patent/CN114040970B/zh active Active
- 2020-02-13 CA CA3128876A patent/CA3128876A1/en active Pending
- 2020-02-13 US US17/430,672 patent/US20230140953A1/en active Pending
- 2020-02-13 WO PCT/US2020/018073 patent/WO2020168051A1/en not_active Ceased
- 2020-02-13 EP EP20756724.9A patent/EP3924484A4/en active Pending
- 2020-02-13 CN CN202411269394.0A patent/CN119280261A/zh active Pending
- 2020-02-13 JP JP2021546888A patent/JP7586601B2/ja active Active
- 2020-02-13 AU AU2020223306A patent/AU2020223306B2/en active Active
- 2020-02-13 KR KR1020217029268A patent/KR20210127206A/ko active Pending
-
2024
- 2024-11-05 JP JP2024193416A patent/JP2025032080A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025032080A5 (cg-RX-API-DMAC7.html) | ||
| Hom et al. | Deep mutational scan of the highly conserved influenza A virus M1 matrix protein reveals substantial intrinsic mutational tolerance | |
| Tsai et al. | Addition of m6A to SV40 late mRNAs enhances viral structural gene expression and replication | |
| Meijer et al. | φ29 family of phages | |
| Feng et al. | Substrate specificity of human protein arginine methyltransferase 7 (PRMT7): the importance of acidic residues in the double E loop | |
| BR112020006786A2 (pt) | composições e métodos para editar rna | |
| JP2022545950A5 (cg-RX-API-DMAC7.html) | ||
| Mathews | Viral evasion of cellular defense mechanisms: regulation of the protein kinase DAI by RNA effectors | |
| JPH05506997A (ja) | オリゴヌクレオチドによるインフルエンザウィルス複製の阻止 | |
| JP2010528617A5 (ja) | リボスイッチならびにリボスイッチを使用するためのおよびリボスイッチと共に使用するための方法および組成物 | |
| EP3212788A2 (en) | Compositions, methods and use of synthetic lethal screening | |
| Ren et al. | Current progress on host antiviral factor IFITMs | |
| Florian et al. | Characterization of the anti‐HBV activity of HLP1–23, a human lactoferrin‐derived peptide | |
| Huang et al. | Involvement of the zinc-binding capacity of Sendai virus V protein in viral pathogenesis | |
| CN121079310A (zh) | 用于治疗与cdkl5缺乏相关的病症的组合物及方法 | |
| FR2780069A1 (fr) | Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications | |
| Jordan-Paiz et al. | Impact of synonymous genome recoding on the HIV life cycle | |
| Zhang et al. | RING finger protein 5 is a key anti-FMDV host factor through inhibition of virion assembly | |
| KR20110049749A (ko) | 양성-센스 단일-사슬 rna 바이러스로의 감염을 예방 또는 치료하기 위한 대형 인간 2´,5´-올리고아데닐레이트 합성효소 oas3 | |
| Schotte et al. | Characterization of poliovirus neutralization escape mutants of single-domain antibody fragments (VHHs) | |
| EP4008343A2 (en) | Methods and compositions related to increased viral production | |
| Tian et al. | AntiV‐SGN: a universal antiviral strategy to combat both RNA and DNA viruses by destroying their nucleic acids without sequence limitation | |
| Baquero-Perez et al. | From A to m6A: The Emerging Viral Epitranscriptome. Viruses 2021, 13, 1049 | |
| CN110214013A (zh) | 抗病毒剂及治疗病毒感染的方法 | |
| Roos | Pathogenesis of Theiler’s murine encephalomyelitis virus‐induced disease |